{"Title": "The MEK1/2 inhibitor pimasertib enhances gemcitabine efficacy-response", "Year": 2016, "Source": "Clin. Cancer Res.", "Volume": "22", "Issue": 10, "Art.No": null, "PageStart": 2595, "PageEnd": null, "CitedBy": 1, "DOI": "10.1158/1078-0432.CCR-16-0566", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84968627150&origin=inward", "Abstract": null, "AuthorKeywords": null, "IndexKeywords": ["Cell Line, Tumor", "Deoxycytidine", "Humans", "Protein Kinase Inhibitors"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-84968627150", "SubjectAreas": [["Oncology", "MEDI", "2730"], ["Cancer Research", "BIOC", "1306"]], "AuthorData": {"57053223700": {"Name": "Vena F.", "AuthorID": "57053223700", "AffiliationID": "60109234, 60022148", "AffiliationName": "UCL Cancer Institute, University College of London"}, "35599970900": {"Name": "Hartley J.", "AuthorID": "35599970900", "AffiliationID": "60109234, 60022148", "AffiliationName": "UCL Cancer Institute, University College of London"}, "6701713285": {"Name": "Hochhauser D.", "AuthorID": "6701713285", "AffiliationID": "60109234", "AffiliationName": "UCL Cancer Institute"}}}